{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T23:51:58Z","timestamp":1777852318083,"version":"3.51.4"},"reference-count":14,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Health and Labor Sciences Research Grant","award":["20DA1008"],"award-info":[{"award-number":["20DA1008"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Hum Lact"],"published-print":{"date-parts":[[2025,2]]},"abstract":"\n Introduction:<\/jats:title>\n Favipiravir is a known anti-influenza agent that has been used globally, especially during the coronavirus disease 2019 (COVID-19) pandemic. This drug has been important for treating influenza and other emerging infectious diseases, although it was ultimately proven to be ineffective for COVID-19. Currently, no studies have reported the human-milk transfer of favipiravir at doses of 1,600\u20133,600\u2009mg\/day in the treatment of diseases, including COVID-19.<\/jats:p>\n <\/jats:sec>\n \n Main Issue:<\/jats:title>\n A 38-year-old mother gave birth at 38 gestational weeks because of severe respiratory distress caused by COVID-19. Considering her illness and the inadequate information available on the safety of favipiravir in breastfeeding, she chose formula feeding for her infant. However, she still provided human milk and blood samples for the analysis of drug concentrations.<\/jats:p>\n <\/jats:sec>\n \n Management:<\/jats:title>\n Five concentrations of favipiravir in the\u2009mother\u2019s milk and four in maternal blood were measured (3.0\u201380.9 and 3.5\u201378.4\u2009\u03bcg\/ml, respectively). Metabolites of favipiravir were not measured. The relative infant dose was 15.2%. The favipiravir concentration in human milk was as high as 80.9\u2009\u03bcg\/ml at 1.3\u2009hours after the medication was given, when maternal blood levels are considered to be at their highest; however, favipiravir concentration was low in human milk immediately before medication administration (5.9\u20139.7\u2009\u03bcg\/ml).<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Breastfeeding is not contraindicated in mothers undergoing favipiravir therapy and would be safer immediately before medication. Avoiding feeding at the peak time (1.3\u2009hours after medication) minimizes infant exposure.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/08903344241296034","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T05:26:08Z","timestamp":1732598768000},"page":"65-69","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety of Breastfeeding During Favipiravir Therapy: A Case Study"],"prefix":"10.1177","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5277-9624","authenticated-orcid":false,"given":"Yuka Sano","family":"Wada","sequence":"first","affiliation":[{"name":"Division of Neonatology, Center for Maternal-Fetal, Neonatal, and Reproductive Medicine, National Center for Child Health and Development, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4799-5562","authenticated-orcid":false,"given":"Jumpei","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Pharmaceuticals, National Center for Child Health and Development, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wakako","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Mie Central Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Maegawa","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Mie Central Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Kamiya","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Showa University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6983-8851","authenticated-orcid":false,"given":"Katsumi","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Showa University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"bibr1-08903344241296034","unstructured":"Avigan. (2017). Avigan tablets 200mg. CDC. Retrieved December 11, 2023, from https:\/\/www.cdc.gov.tw\/File\/Get\/ht8jUiB_MI-aKnlwstwzvw"},{"key":"bibr2-08903344241296034","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2021.122768"},{"key":"bibr3-08903344241296034","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.04.035"},{"key":"bibr4-08903344241296034","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068347"},{"key":"bibr5-08903344241296034","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1154814"},{"key":"bibr6-08903344241296034","doi-asserted-by":"publisher","DOI":"10.5152\/TurkArchPediatr.2021.21117"},{"key":"bibr7-08903344241296034","author":"Korula P.","year":"2024","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"bibr8-08903344241296034","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00016-0"},{"key":"bibr9-08903344241296034","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X20964046"},{"key":"bibr10-08903344241296034","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00412-X"},{"key":"bibr11-08903344241296034","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.115131"},{"key":"bibr12-08903344241296034","unstructured":"United States Department of Health and Human Services, Food, Drug Administration, Center for Drug Evaluation and Research, & Center for Veterinary Medicine. (2018). Bioanalytical method validation guidance for industry. Biopharmaceutics. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf"},{"key":"bibr13-08903344241296034","doi-asserted-by":"publisher","DOI":"10.3390\/arm91010004"},{"key":"bibr14-08903344241296034","volume-title":"Liquid chromatography-mass spectrometry methods; approved guidelines","author":"Wayne P. A.","year":"2014"}],"container-title":["Journal of Human Lactation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08903344241296034","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08903344241296034","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08903344241296034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:34:28Z","timestamp":1777502068000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08903344241296034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1177\/08903344241296034"],"URL":"https:\/\/doi.org\/10.1177\/08903344241296034","relation":{},"ISSN":["0890-3344","1552-5732"],"issn-type":[{"value":"0890-3344","type":"print"},{"value":"1552-5732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]}}}